Recently, the latest Lung-molGPA score incorporating gene alteration data (EGFR mutation/ALK rearrangement) is widely used to assess patient survival in NSCLC with brain metastases and facilitate clinical decision making.14 The gene discussed is ALK; the disease is non-small cell lung carcinoma.